7 February 2017 - From 7 February, children aged two to five will have immediate and free access to Kalydeco (ivacaftor) – a life-changing drug that addresses the causes of cystic fibrosis rather than just the symptoms.

From today, children aged two to five will have immediate and free access to Kalydeco (ivacaftor) – a life-changing drug that addresses the causes of cystic fibrosis rather than just the symptoms.

Previously, only children six years of age and older with the G551D or other class III gating mutations had subsidised access to Kalydeco.

Expanding access to this vital drug is fantastic news for Australian families. We know that many parents have been worried about how their young son or daughter could get access to this life-changing drug. Now they have it.

Without government subsidy, the treatment would cost each patient around $300,000 per year.

Read Minister of Health press release